KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $141.7 million.

  • Nektar Therapeutics' Cash from Financing Activities rose 1089723.08% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.0 million, marking a year-over-year increase of 237.66%. This contributed to the annual value of $42.1 million for FY2024, which is 140293.33% up from last year.
  • Per Nektar Therapeutics' latest filing, its Cash from Financing Activities stood at $141.7 million for Q3 2025, which was up 67,045.50% from $211,000 recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Cash from Financing Activities peaked at $141.7 million during Q3 2025, and registered a low of $7,000 during Q1 2025.
  • Its 3-year average for Cash from Financing Activities is $20.4 million, with a median of $19,000 in 2024.
  • The largest annual percentage gain for Nektar Therapeutics' Cash from Financing Activities in the last 5 years was 1,089,723.08% (2025), contrasted with its biggest fall of 99.98% (2025).
  • Nektar Therapeutics' Cash from Financing Activities (Quarterly) stood at $2.6 million in 2021, then slumped by 95.96% to $103,000 in 2022, then crashed by 88.35% to $12,000 in 2023, then skyrocketed by 591.67% to $83,000 in 2024, then spiked by 1,089,723.08% to $141.7 million in 2025.
  • Its Cash from Financing Activities stands at $141.7 million for Q3 2025, versus $211,000 for Q2 2025 and $7,000 for Q1 2025.